Two Sigma Investments LP Makes New Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Two Sigma Investments LP bought a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 33,025 shares of the biopharmaceutical company's stock, valued at approximately $835,000.

Several other hedge funds have also bought and sold shares of the company. EverSource Wealth Advisors LLC increased its position in Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 878 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of Celldex Therapeutics during the 4th quarter worth approximately $81,000. KBC Group NV increased its holdings in shares of Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 1,647 shares during the last quarter. AlphaQuest LLC raised its stake in Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after acquiring an additional 2,705 shares during the period. Finally, Aquatic Capital Management LLC acquired a new stake in Celldex Therapeutics during the 4th quarter valued at $121,000.

Analyst Ratings Changes

Several equities analysts have commented on CLDX shares. Canaccord Genuity Group assumed coverage on shares of Celldex Therapeutics in a report on Monday, April 28th. They issued a "buy" rating and a $64.00 price objective on the stock. Morgan Stanley reduced their target price on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Friday, May 9th. The Goldman Sachs Group lowered their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. UBS Group reduced their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, May 6th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Celldex Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $53.90.

Celldex Therapeutics Stock Up 1.0%

Shares of CLDX traded up $0.21 during mid-day trading on Tuesday, hitting $20.92. 992,491 shares of the company's stock were exchanged, compared to its average volume of 919,801. Celldex Therapeutics, Inc. has a 52 week low of $14.40 and a 52 week high of $47.00. The stock's 50-day simple moving average is $19.05 and its 200-day simple moving average is $21.90. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -8.14 and a beta of 1.33.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.